Liver Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Targeted Therapy, Immunotherapy), By Country (U.S., Japan, U.K., Germany, Spain, Italy, France), And Segment Forecasts, 2016 - 2022
This report can be delivered to the clients within 48 Hours
The global liver cancer drugs market size is expected to be valued at USD 1.47 billion by 2022, as per a new report by Grand View Research, Inc., expanding at a CAGR of 19.4% during the forecast period. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.
Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75–90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.
Further key findings from the report suggest:
The global liver cancer drugs market size is expected to be valued at USD 1.47 billion by 2022, as per a new report by Grand View Research, Inc., expanding at a CAGR of 19.4% during the forecast period. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.
Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75–90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.
Further key findings from the report suggest:
- The U.S. accounted for more than 45.0% of the market in 2016. Multiple product launches, increasing adoption of novel therapeutics, and presence of a large target population are contributing to the growth of the market in the region
- Approval of multiple novel drugs in recent years is one of the key factors augmenting the liver cancer treatment market. New immuno-oncology products and combination therapies are anticipated to change the landscape over the next years.
- Combination regimens, specifically those including checkpoint inhibitors, will be introduced in the first-line setting to target major unmet needs, including overcoming tumour resistance, improving progression free survival, and maintaining quality of life
- The liver cancer market pipeline is highly innovative and diverse. The market offers tremendous opportunities to develop breakthrough first-in-class therapies due to high unmet needs. In recent years, innovative treatment approaches such as oncolytic viruses or RNA interference (RNAi) technology have gained significant traction in the market
- Some of the key players operating in this market are Bayer, Bristol-Myers Squibb, Eisai, and Exelixis. Collaborations for development, broader product portfolios, and regional expansion in emerging markets are the key strategic undertakings of these companies to increase their market share.
CHAPTER 1 RESEARCH METHODOLOGY
1.1. Information procurement
1.2. Information or Data Analysis
1.2.1 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1. Disease Primer
3.2. Epidemiology
CHAPTER 4 GLOBAL LIVER CANCER DRUGS MARKET OVERVIEW
4.1 Market by Therapeutic Class
4.2 Market Size and Forecast 2016 - 2022
4.3 Market Share Distribution, by Company 2016 - 2022
4.4 Market Dynamics and Brand Strategies
4.5 Patent Expiry Analysis
4.6 Liver Cancer Market: Drivers and Restraints
4.6.1 Drivers
4.6.2 Challenges
4.7 M&A, Deal Landscape (2013 - 2017 YTD)
4.7.1 Mergers & Acquisitions
4.7.2 Deals Landscape
4.8 Emerging Markets
4.9 Reimbursement Scenario
4.10 Liver Cancer Sector SWOT
CHAPTER 5 LIVER CANCER MARKET: PIPELINE INTELLIGENCE
5.1. Pipeline Landscape
5.1.1 Leading Drugs in Development
5.1.2 Key R&D Trends
5.2 Pipeline Landscape
5.2.1 Late Stage Pipeline and Sales Forecast
5.2.2 Profiles of Disruptive Drugs
5.3 Global Pipeline Forecast
CHAPTER 6 COMPANY PROFILES
6.1 Bayer
6.1.1 Company Overview
6.1.2 Current Product Portfolio
6.1.3 Product Forecast Sales Through 2022
6.1.4 Strategic Initiatives
6.1.4.1 Key Company News Flow
6.1.5 Pipeline Analysis & Overview
6.1.6 SWOT
6.2 Bristol-Myers Squibb
6.2.1 Company Overview
6.2.2 Current Product Portfolio
6.2.3 Product Forecast Sales Through 2022
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.5 Pipeline Analysis & Overview
6.2.6 SWOT
6.3 Eisai
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales Through 2022
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.5 Pipeline Analysis & Overview
6.3.6 SWOT
6.4 Exelixis
6.4.1 Company Overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales Through 2022
6.4.4 Strategic Initiatives
6.4.4.1 Key Company News Flow
6.4.5 Pipeline Analysis & Overview
6.4.6 SWOT
6.5 Merck
6.5.1 Company Overview
6.5.2 Current Product Portfolio
6.5.3 Product Forecast Sales Through 2022
6.5.4 Strategic Initiatives
6.5.4.1 Key Company News Flow
6.5.5 Pipeline Analysis & Overview
6.5.6 SWOT
CHAPTER 7 MARKET OUTLOOK
7.1 What the Future Holds
7.2 The Winners and Losers
7.2.1 Winners
7.2.2 Losers
7.3 Emerging Companies & Technology Platforms
7.4 The Road Ahead
1.1. Information procurement
1.2. Information or Data Analysis
1.2.1 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1. Disease Primer
3.2. Epidemiology
CHAPTER 4 GLOBAL LIVER CANCER DRUGS MARKET OVERVIEW
4.1 Market by Therapeutic Class
4.2 Market Size and Forecast 2016 - 2022
4.3 Market Share Distribution, by Company 2016 - 2022
4.4 Market Dynamics and Brand Strategies
4.5 Patent Expiry Analysis
4.6 Liver Cancer Market: Drivers and Restraints
4.6.1 Drivers
4.6.2 Challenges
4.7 M&A, Deal Landscape (2013 - 2017 YTD)
4.7.1 Mergers & Acquisitions
4.7.2 Deals Landscape
4.8 Emerging Markets
4.9 Reimbursement Scenario
4.10 Liver Cancer Sector SWOT
CHAPTER 5 LIVER CANCER MARKET: PIPELINE INTELLIGENCE
5.1. Pipeline Landscape
5.1.1 Leading Drugs in Development
5.1.2 Key R&D Trends
5.2 Pipeline Landscape
5.2.1 Late Stage Pipeline and Sales Forecast
5.2.2 Profiles of Disruptive Drugs
5.3 Global Pipeline Forecast
CHAPTER 6 COMPANY PROFILES
6.1 Bayer
6.1.1 Company Overview
6.1.2 Current Product Portfolio
6.1.3 Product Forecast Sales Through 2022
6.1.4 Strategic Initiatives
6.1.4.1 Key Company News Flow
6.1.5 Pipeline Analysis & Overview
6.1.6 SWOT
6.2 Bristol-Myers Squibb
6.2.1 Company Overview
6.2.2 Current Product Portfolio
6.2.3 Product Forecast Sales Through 2022
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.5 Pipeline Analysis & Overview
6.2.6 SWOT
6.3 Eisai
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales Through 2022
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.5 Pipeline Analysis & Overview
6.3.6 SWOT
6.4 Exelixis
6.4.1 Company Overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales Through 2022
6.4.4 Strategic Initiatives
6.4.4.1 Key Company News Flow
6.4.5 Pipeline Analysis & Overview
6.4.6 SWOT
6.5 Merck
6.5.1 Company Overview
6.5.2 Current Product Portfolio
6.5.3 Product Forecast Sales Through 2022
6.5.4 Strategic Initiatives
6.5.4.1 Key Company News Flow
6.5.5 Pipeline Analysis & Overview
6.5.6 SWOT
CHAPTER 7 MARKET OUTLOOK
7.1 What the Future Holds
7.2 The Winners and Losers
7.2.1 Winners
7.2.2 Losers
7.3 Emerging Companies & Technology Platforms
7.4 The Road Ahead
LIST OF TABLES
Table 1 Marketed Drugs for Liver Cancer
Table 2 Sales Performance by Therapeutic Class, 2016 -
Table 3 Sales Performance by Geographic Market, in $ million, 2016 -
Table 4 U.S. Patents for Current Liver Cancer Drugs
Table 5 R&D Pipeline Overview
Table 6 Gene Therapy Pipeline
Table 7 Late Stage Pipeline
Table 8 Lenvima
Table 9 Cabometyx
Table 10 Keytruda
Table 11 Cyramza
Table 12 Pexa - Vec (JX - 594)
Table 13 Pipeline Forecast of Leading Drugs
Table 14 Bayer Sales Forecast, 2016 - 2022
Table 15 Bayer Pipeline
Table 16 Bristol - Myers Squibb Sales Forecast, 2016 - 2022
Table 17 Bristol - Myers Squibb Pipeline
Table 18 Eisai Sales Forecast, 2016 - 2022
Table 19 Exelixis Sales Forecast, 2016 - 2022
Table 20 Exelixis Pipeline
Table 21 Merck Sales Forecast, 2016 - 2022LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Incidence and Mortality Rate of Liver Cancer per 100,000 in the U.S. (2000 - 12)
Fig. 8 Incidence and Mortality Rate of Liver Cancer per 100,000 in Japan (2000 - 12)
Fig. 9 Incidence and Mortality Rate of Liver Cancer per 100,000 in the U.K. (2000 - 12)
Fig. 10 Incidence and Mortality Rate of Liver Cancer per 100,000 in Spain (2000 - 12)
Fig. 11 Incidence and Mortality Rate of Liver Cancer per 100,000 in France (2000 - 12)
Fig. 12 Incidence and Mortality Rate of Liver Cancer per 100,000 in Italy (2000 - 12)
Fig. 13 Incidence and Mortality Rate of Liver Cancer per 100,000 in Germany (2000 - 12)
Fig. 14 Liver Cancer Market Share, by Therapeutic Class, 2016 -
Fig. 15 Regional Market Size, 2016 - 2022
Fig. 16 U.S. Liver Cancer Drugs Market, $ million (2016 - 22)
Fig. 17 Japan Liver Cancer Drugs Market, $ million (2016 - 22)
Fig. 18 Germany Liver Cancer Drugs Market, $ million (2016 - 22)
Fig. 19 France Liver Cancer Drugs Market, $ million (2016 - 22)
Fig. 20 U.K. Liver Cancer Drugs Market, $ million (2016 - 22)
Fig. 21 Italy Liver Cancer Drugs Market, $ million (2016 - 22)
Fig. 22 Spain Liver Cancer Drugs Market, $ million (2016 - 22)
Fig. 23 Liver Cancer Market Share, by Company, 2016 -
Fig. 24 Incidence and Mortality Rate of Liver Cancer per 100,000 in China (2000 - 12)
Fig. 25 Liver Cancer Market SWOT
Fig. 26 Bayer HCC Sales Forecast
Fig. 27 Bayer SWOT Analysis
Fig. 28 Bristol - Myers Squibb HCC Sales Forecast
Fig. 29 Bristol - Myers Squibb SWOT Analysis
Fig. 30 Eisai HCC Sales Forecast
Fig. 31 Eisai SWOT Analysis
Fig. 32 Exelixis HCC Sales Forecast
Fig. 33 Exelixis SWOT Analysis
Fig. 34 Merck HCC Sales Forecast
Fig. 35 Merck SWOT Analysis
Table 1 Marketed Drugs for Liver Cancer
Table 2 Sales Performance by Therapeutic Class, 2016 -
Table 3 Sales Performance by Geographic Market, in $ million, 2016 -
Table 4 U.S. Patents for Current Liver Cancer Drugs
Table 5 R&D Pipeline Overview
Table 6 Gene Therapy Pipeline
Table 7 Late Stage Pipeline
Table 8 Lenvima
Table 9 Cabometyx
Table 10 Keytruda
Table 11 Cyramza
Table 12 Pexa - Vec (JX - 594)
Table 13 Pipeline Forecast of Leading Drugs
Table 14 Bayer Sales Forecast, 2016 - 2022
Table 15 Bayer Pipeline
Table 16 Bristol - Myers Squibb Sales Forecast, 2016 - 2022
Table 17 Bristol - Myers Squibb Pipeline
Table 18 Eisai Sales Forecast, 2016 - 2022
Table 19 Exelixis Sales Forecast, 2016 - 2022
Table 20 Exelixis Pipeline
Table 21 Merck Sales Forecast, 2016 - 2022LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Incidence and Mortality Rate of Liver Cancer per 100,000 in the U.S. (2000 - 12)
Fig. 8 Incidence and Mortality Rate of Liver Cancer per 100,000 in Japan (2000 - 12)
Fig. 9 Incidence and Mortality Rate of Liver Cancer per 100,000 in the U.K. (2000 - 12)
Fig. 10 Incidence and Mortality Rate of Liver Cancer per 100,000 in Spain (2000 - 12)
Fig. 11 Incidence and Mortality Rate of Liver Cancer per 100,000 in France (2000 - 12)
Fig. 12 Incidence and Mortality Rate of Liver Cancer per 100,000 in Italy (2000 - 12)
Fig. 13 Incidence and Mortality Rate of Liver Cancer per 100,000 in Germany (2000 - 12)
Fig. 14 Liver Cancer Market Share, by Therapeutic Class, 2016 -
Fig. 15 Regional Market Size, 2016 - 2022
Fig. 16 U.S. Liver Cancer Drugs Market, $ million (2016 - 22)
Fig. 17 Japan Liver Cancer Drugs Market, $ million (2016 - 22)
Fig. 18 Germany Liver Cancer Drugs Market, $ million (2016 - 22)
Fig. 19 France Liver Cancer Drugs Market, $ million (2016 - 22)
Fig. 20 U.K. Liver Cancer Drugs Market, $ million (2016 - 22)
Fig. 21 Italy Liver Cancer Drugs Market, $ million (2016 - 22)
Fig. 22 Spain Liver Cancer Drugs Market, $ million (2016 - 22)
Fig. 23 Liver Cancer Market Share, by Company, 2016 -
Fig. 24 Incidence and Mortality Rate of Liver Cancer per 100,000 in China (2000 - 12)
Fig. 25 Liver Cancer Market SWOT
Fig. 26 Bayer HCC Sales Forecast
Fig. 27 Bayer SWOT Analysis
Fig. 28 Bristol - Myers Squibb HCC Sales Forecast
Fig. 29 Bristol - Myers Squibb SWOT Analysis
Fig. 30 Eisai HCC Sales Forecast
Fig. 31 Eisai SWOT Analysis
Fig. 32 Exelixis HCC Sales Forecast
Fig. 33 Exelixis SWOT Analysis
Fig. 34 Merck HCC Sales Forecast
Fig. 35 Merck SWOT Analysis
